Ashu Madan, president of core client group at Religare Securities advised buying Dishman Pharma at current levels. In short-term, the stock can go up by 10-15 percent, feels Madan.
first published: May 29, 2013 07:50 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends gain to the second straight day but sees another weekly loss | Closing Bell
Live: Can Nifty extend gains and reclaim 26,000? | Opening Bell
FSS Simply Payments 2025 | AI in Payments: Building a Governance-First Future.
Live: Nifty reclaims 25,900, snaps 3-day losing streak; rupee falls to fresh low | Closing Bell
